Kymera Therapeutics Current Cash

Kymera Therapeutics's current cash stands at $120M as of June 2026. That compares with $340M in the prior-year period — down 62.9% year over year. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Kymera Therapeutics reported $120M in current cash versus $340M a year earlier — a 62.9% year-over-year decrease. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

That compares with $340M in the prior-year period — down 62.9% year over year. Sustained growth in current cash can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how Kymera Therapeutics's current cash evolved across reporting periods, while the comparison chart places KYMR next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, current cash is commonly used to spot outliers. Kymera Therapeutics's reading of $120M is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.